CAY10574

Modify Date: 2024-01-14 20:18:14

CAY10574 Structure
CAY10574 structure
Common Name CAY10574
CAS Number 140651-18-9 Molecular Weight 218.215
Density 1.7±0.1 g/cm3 Boiling Point 638.3±55.0 °C at 760 mmHg
Molecular Formula C9H10N6O Melting Point N/A
MSDS N/A Flash Point 339.8±31.5 °C

 Use of CAY10574


CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].

 Names

Name 4-[(3,5-diamino-1H-pyrazol-4-yl)hydrazinylidene]cyclohexa-2,5-dien-1-one
Synonym More Synonyms

 CAY10574 Biological Activity

Description CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].
Related Catalog
Target

CDK9/cyclinT1:0.35 μM (IC50)

CDK2/cyclinE:20 μM (IC50)

cdk2/cyclin A:69 μM (IC50)

Cdk4/cyclin D1:13.5 μM (IC50)

CDK7/cyclin H:26 μM (IC50)

Cdk1/cyclin B:44 μM (IC50)

In Vitro CAN508 reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays[1]. CAN508 (20-40 μM; 72 hours) significantly reduces cell proliferation in a dose dependent manner in all three esophageal adenocarcinoma cell lines (SKGT4, OE33 and FLO-1 cells) with IC50s ranging from 34.99 to 91.09 μM[2]. CAN508 (40 μM; 72 hours) increases apoptosis in all three esophageal adenocarcinoma cells[2]. Apoptosis Analysis[1] Cell Line: SKGT4, OE33 and FLO-1 cells Concentration: 40 μM Incubation Time: 72 hours Result: Increased apoptosis by 2 fold in all three esophageal adenocarcinoma cells compared to untreated controls.
In Vivo CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts[1]. Animal Model: 4 weeks-old female nude mice (esophageal adenocarcinoma xenografts)[1] Dosage: 60 mg/kg Administration: I.p.; daily for 10 days Result: Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.
References

[1]. Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509.

[2]. Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710.

 Chemical & Physical Properties

Density 1.7±0.1 g/cm3
Boiling Point 638.3±55.0 °C at 760 mmHg
Molecular Formula C9H10N6O
Molecular Weight 218.215
Flash Point 339.8±31.5 °C
Exact Mass 218.091614
PSA 125.67000
LogP 0.40
Vapour Pressure 0.0±2.0 mmHg at 25°C
Index of Refraction 1.803

 Synonyms

3tn8
2clx
Cdk9 Inhibitor II
Phenol, 4-[(E)-2-(3,5-diamino-1H-pyrazol-4-yl)diazenyl]-
4-[(E)-(3,5-Diamino-1H-pyrazol-4-yl)diazenyl]phenol
F18
CAN-508
Top Suppliers:I want be here



Get all suppliers and price by the below link:

CAY10574 suppliers


Price: ¥4000/5 mg

Reference only. check more CAY10574 price

Hot Compounds More...
Dichloromethane
CAS#:75-09-2
Polyacrylic acid
CAS#:9003-01-4
sodium carbonate
CAS#:497-19-8
Silicon dioxide
CAS#:7631-86-9
Triethanolamine
CAS#:102-71-6
Demeton
CAS#:126-75-0
Water
CAS#:7732-18-5
4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9
Diclofenac sodium
CAS#:15307-79-6
Budesonide
CAS#:51372-29-3